Community Statements on DRV/r Use in 2L
In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global...
top of page
A framework to support new product introduction in national health systems
Resource Library
- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
157
- Mar 22, 2022
Customizable Adult DRV/r (400/50mg) Healthcare Worker Training Slides
CHAI has developed a generic training curriculum that is intended to be adapted for local contexts and their respective training plans.
90
- Mar 17, 2022
CHAI DRV/r 2L Product Profile
A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.
137
- Mar 17, 2022
DRV/r (400/50mg) FAQs
CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...
68
- May 28, 2020
Optimizing 2L HIV Treatment with DTG-based Regimens
This memo highlights the patient benefits, cost savings and improved supply security associated with proactively switching eligible 2L...
12
- Feb 4, 2020
CHAI Cost of Optimizing Second-Line Treatment (COST) Tool
The CHAI COST Tool is a model that helps to estimate the financial impact of switching existing second-line (2L) patients to optimized,...
24
bottom of page